GLP-1s and Bariatric Surgery

These get framed as competing answers, usually by people invested in one of them. In clinic they increasingly appear in sequence, and there are four distinct situations worth separating.

1. After surgery, for weight recurrence

This is the commonest version and the one with the clearest rationale.

Weight regain affects a substantial proportion of people in the 2–5 years after bariatric surgery. It is not a failure of will — the same biological defence of body weight that made the original weight difficult reasserts itself, and the anatomical change loses some of its effect over time. Historically the options were limited, and revision surgery carries higher risk than the original operation.

Adding a GLP-1 for recurrence, often 12–24 months or more after the operation, is now common practice and is one of the better-supported uses of the combination.

What does not change is the nutrition. Bariatric surgery alters absorption as well as volume, which is why lifelong supplementation and monitoring are standard. Adding a drug that further reduces intake stacks a second restriction on top of an altered gut. The deficiencies to watch are the surgical ones — iron, B12, vitamin D, calcium, thiamine, folate — and the monitoring schedule continues unchanged.

The general argument in the multivitamin rankings draws on the bariatric literature precisely because it is the best-studied model of eating very little for a long time. After actual surgery you are not in the analogy; you are in the original.

2. Instead of surgery

The honest comparison:

Surgery still produces greater average loss and has the longest outcome record, including mortality benefit in cohort studies. The gap has narrowed — SURMOUNT-1 reported 20.9% at 72 weeks on top-dose tirzepatide, which enters the range of some sleeve outcomes — but they are not equivalent.

The genuine trade is between a one-time procedure with permanent anatomical change and an indefinite medication whose effect ends when it does. Neither is obviously correct, and the regain data in what happens when you stop is the part people underweight when choosing the medication.

3. Before surgery

Some programmes use pharmacotherapy pre-operatively to reduce liver volume and operative risk. That is a specific clinical purpose decided by the surgical team.

What matters if you are already on a GLP-1 and surgery is planned is the anaesthetic. These drugs delay gastric emptying, so your stomach may not be empty after a standard overnight fast — an aspiration risk that has changed pre-operative practice across the field.

Tell the team at booking, not on the day. Expect a plan that may include a clear-liquid period, an extended fast, gastric ultrasound, or a modified airway approach — and know that holding one weekly dose does not clear a drug with a 7-day half-life. The full detail is in GLP-1s, surgery and procedures.

4. Never having had surgery, and wondering

The considerations that usually decide it: your starting BMI and comorbidities, whether you can access and sustain a medication indefinitely, how you feel about permanent anatomical change, and whether you have conditions where one has specific evidence — obstructive sleep apnea, heart failure with preserved ejection fraction, chronic kidney disease and knee osteoarthritis now all have GLP-1 trial data attached, covered in sleep apnea, heart failure, kidney disease and knee osteoarthritis.

This is a conversation with a clinician who does both, and there are fewer of those than there should be.

The muscle problem, doubled

Both interventions cause lean tissue loss. Doing them in sequence, or in combination, without a plan is how someone arrives at a normal BMI with meaningfully worse function.

The requirements do not change but the discipline has to: protein at 1.2–1.6 g/kg a day, and 2 resistance sessions a week. After surgery, hitting a protein target from food is genuinely difficult, which is why a supplement stops being optional — the options are in the protein powder rankings.

What I would ask for

• Who owns the nutritional monitoring, if you are under both a surgeon and a prescriber — the commonest failure is each assuming the other is doing it
• A written supplement regimen and a blood test schedule, and whether the GLP-1 changes either
• A protein target, and a plan for reaching it given your anatomy
• The anaesthetic conversation, at booking, if any procedure is coming
• What happens if the medication becomes unavailable — supply gaps are common, and restarting after a break is not simply resuming your old dose, as what to do if you miss a dose sets out